Trial Profile
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development
- 19 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 22 Jun 2012 Official Title amended as reported by European Clinical Trials Database record.